Mr. Stephen Kilmer reports

PROFOUND MEDICAL ANNUAL GENERAL MEETING OF SHAREHOLDERS VOTING RESULTS

Profound Medical Corp. has released the voting results from its annual general meeting of shareholders that was held today. A total of 15,336,388 common shares, representing 62.78 per cent of the common shares outstanding, were represented in person and by proxy at the meeting.

All of the matters put forward before the shareholders, as set out in the company's management information circular dated April 5, 2024, were approved by the requisite majority of votes cast at the meeting.

Election of directors

At the meeting, the shareholders of the company elected all six nominees for the board of directors. Detailed results of the voting in respect of the election of directors are as shown in the attached table.

Other matters

The company's shareholders also approved the appointment of PricewaterhouseCoopers LLP as the auditor for the company to hold office until the close of the next annual meeting or until its successor is duly appointed at such remuneration as may be determined by the board of directors. Detailed voting results for all resolutions will be posted under the company's profile on SEDAR+.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing Tulsa-Pro, a technology that combines real-time MRI (magnetic resonance imaging), robotically driven transurethral ultrasound and closed-loop temperature feedback control. Tulsa-Pro is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient's natural functional abilities. Tulsa-Pro has the potential to be a flexible technology in customizable prostate ablation, including intermediate-stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large-volume benign prostatic hyperplasia (BPH). Tulsa-Pro is CE (Conformite Europeenne) marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (FDA).

Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a humanitarian device exemption for the treatment of osteoid osteoma. The company is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

We seek Safe Harbor.